Keith Wilcoxen

2.8k total citations · 1 hit paper
56 papers, 2.2k citations indexed

About

Keith Wilcoxen is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Keith Wilcoxen has authored 56 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 19 papers in Oncology and 16 papers in Organic Chemistry. Recurrent topics in Keith Wilcoxen's work include PARP inhibition in cancer therapy (13 papers), Synthesis and Biological Evaluation (7 papers) and Stress Responses and Cortisol (7 papers). Keith Wilcoxen is often cited by papers focused on PARP inhibition in cancer therapy (13 papers), Synthesis and Biological Evaluation (7 papers) and Stress Responses and Cortisol (7 papers). Keith Wilcoxen collaborates with scholars based in United States, United Kingdom and Denmark. Keith Wilcoxen's co-authors include M. Reza Ghadiri, Dana A. Weinberger, Juan R. Granja, Georgina V. Long, Mercedes Delgado, Karin Kraehenbuehl, Alisher Khasanov, James R. McCarthy, Chen Chen and Chen Chen and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Keith Wilcoxen

56 papers receiving 2.1k citations

Hit Papers

Antibacterial agents based on the cyclic d,l-α-peptide ar... 2001 2026 2009 2017 2001 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antibacterial agents based on the cyclic d,l-α-peptide architecture
    2001 805 citations Keith Wilcoxen, M. Reza Ghadiri et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith Wilcoxen United States 23 1.1k 806 398 341 314 56 2.2k
Vincent Lisowski France 21 1.4k 1.2× 907 1.1× 159 0.4× 251 0.7× 359 1.1× 58 2.3k
Luca Gentilucci Italy 30 2.1k 1.9× 1.5k 1.8× 160 0.4× 237 0.7× 210 0.7× 146 3.3k
E. T. Kaiser United States 27 2.1k 1.9× 274 0.3× 167 0.4× 121 0.4× 400 1.3× 30 2.9k
Marc Devocelle Ireland 29 1.3k 1.2× 448 0.6× 149 0.4× 320 0.9× 334 1.1× 83 2.4k
Spiros Liras United States 34 3.3k 3.0× 2.0k 2.5× 162 0.4× 476 1.4× 637 2.0× 60 4.8k
Gunnar Lindeberg Sweden 30 1.4k 1.3× 632 0.8× 135 0.3× 346 1.0× 237 0.8× 89 2.7k
Christophe Dugave France 24 1.3k 1.1× 847 1.1× 96 0.2× 247 0.7× 103 0.3× 60 3.2k
Michael K. Dunn United States 6 1.2k 1.1× 265 0.3× 98 0.2× 157 0.5× 262 0.8× 6 1.6k
Miklos Bodanszky United States 38 3.7k 3.3× 2.0k 2.5× 217 0.5× 447 1.3× 204 0.6× 139 5.2k
Roger W. Roeske United States 26 1.8k 1.7× 411 0.5× 73 0.2× 241 0.7× 46 0.1× 58 2.5k

Countries citing papers authored by Keith Wilcoxen

Since Specialization
Citations

This map shows the geographic impact of Keith Wilcoxen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Wilcoxen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Wilcoxen more than expected).

Fields of papers citing papers by Keith Wilcoxen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Wilcoxen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Wilcoxen. The network helps show where Keith Wilcoxen may publish in the future.

Co-authorship network of co-authors of Keith Wilcoxen

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Wilcoxen. A scholar is included among the top collaborators of Keith Wilcoxen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Wilcoxen. Keith Wilcoxen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Essalmani, Rachid, Jaspreet Jain, Delia Susan‐Resiga, et al.. (2022). Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity. Journal of Virology. 96(8). e0012822–e0012822. 113 indexed citations
2.
Reihill, James, Melisa W-Y. Ho, Jeffrey M. Axten, et al.. (2022). A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease. Cell chemical biology. 29(6). 947–957.e8. 18 indexed citations
3.
Póti, Ádám, Yonghong Xiao, Orsolya Pipek, et al.. (2018). Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts. British Journal of Cancer. 119(11). 1392–1400. 22 indexed citations
4.
Srinivasan, Gayathri, Gurjit Sidhu, Elizabeth A. Williamson, et al.. (2017). Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemotherapy and Pharmacology. 80(4). 861–867. 46 indexed citations
5.
AlHilli, Mariam, Marc A. Becker, S. John Weroha, et al.. (2016). In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology. 143(2). 379–388. 49 indexed citations
6.
Kehry, Marilyn R., et al.. (2016). Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody. European Journal of Cancer. 69. S102–S102. 21 indexed citations
7.
Wilcoxen, Keith, Marc A. Becker, Christopher Neff, et al.. (2015). Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.. Journal of Clinical Oncology. 33(15_suppl). 5532–5532. 11 indexed citations
8.
Martell, Robert E., et al.. (2013). Discovery of Novel Drugs for Promising Targets. Clinical Therapeutics. 35(9). 1271–1281. 13 indexed citations
9.
Wilcoxen, Keith, Taisuke Uehara, Khin Than Myint, Yoshiaki Sato, & Yoshiya Oda. (2010). Practical metabolomics in drug discovery. Expert Opinion on Drug Discovery. 5(3). 249–263. 24 indexed citations
10.
Wilcoxen, Keith, et al.. (2007). Recent Advances of MEK Inhibitors and Their Clinical Progress. Current Topics in Medicinal Chemistry. 7(14). 1364–1378. 61 indexed citations
11.
Horne, W. Seth, Christopher M. Wiethoff, Keith Wilcoxen, et al.. (2005). Antiviral cyclic d,l-α-peptides: Targeting a general biochemical pathway in virus infections. Bioorganic & Medicinal Chemistry. 13(17). 5145–5153. 105 indexed citations
12.
Huang, Charles Q., Keith Wilcoxen, Dimitri E. Grigoriadis, James R. McCarthy, & Chen Chen. (2004). Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 14(15). 3943–3947. 29 indexed citations
13.
Chen, Chen, Keith Wilcoxen, Charles Q. Huang, et al.. (2004). Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility. Bioorganic & Medicinal Chemistry Letters. 14(14). 3669–3673. 22 indexed citations
14.
Zhu, Yunfei, Xiaochuan Wang, Patrick J. Connors, et al.. (2003). Quinoline-Carboxylic acids are potent inhibitors that inhibit the binding of insulin-Like growth factor (IGF) to IGF-Binding proteins. Bioorganic & Medicinal Chemistry Letters. 13(11). 1931–1934. 23 indexed citations
15.
Huang, Charles Q., Keith Wilcoxen, James R. McCarthy, et al.. (2003). Synthesis and SAR of 8-Arylquinolines as potent corticotropin-Releasing factor1 (CRF1) receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 13(19). 3375–3379. 20 indexed citations
16.
Wilcoxen, Keith, Charles Q. Huang, James R. McCarthy, Dimitri E. Grigoriadis, & Chen Chen. (2003). Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-Releasing factor receptor type-1 antagonists. Bioorganic & Medicinal Chemistry Letters. 13(19). 3367–3370. 11 indexed citations
17.
18.
Zhu, Yunfei, Keith Wilcoxen, Timothy D. Gross, et al.. (2003). 6,7-Dihydroxyisoquinoline-3-carboxylic acids are potent inhibitors on the binding of insulin-Like growth factor (IGF) to IGF-binding proteins: optimization of the 1-position benzoyl side chain. Bioorganic & Medicinal Chemistry Letters. 13(11). 1927–1930. 9 indexed citations
19.
Wilcoxen, Keith, Patrick J. Connors, John Saunders, et al.. (2002). Synthesis and initial structure–Activity relationships of a novel series of imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 12(16). 2179–2183. 25 indexed citations
20.
Gross, Timothy D., John Saunders, Keith Wilcoxen, et al.. (2002). Design, synthesis and structure–Activity relationships of novel imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 12(16). 2185–2187. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincent Lisowski Breakdown of academic impact, for papers by Luca Gentilucci Breakdown of academic impact, for papers by E. T. Kaiser Breakdown of academic impact, for papers by Marc Devocelle Breakdown of academic impact, for papers by Spiros Liras Breakdown of academic impact, for papers by Gunnar Lindeberg Breakdown of academic impact, for papers by Christophe Dugave Breakdown of academic impact, for papers by Michael K. Dunn Breakdown of academic impact, for papers by Miklos Bodanszky Breakdown of academic impact, for papers by Roger W. Roeske
Rankless by CCL
2026